11.12.24 -- Emerging Partnership Trends In Oligo-Based Medicines

There are two basic models of pharma manufacturing: batch and continuous. Here, we compare the two and examine the challenges they bring to containment product design.

Choosing the right packaging partner for your probiotic may be the most crucial step to ensuring your product is safe and potent when it reaches the consumer.

Discover how ongoing process verification, guided by PAT and digital integration, ensures consistent cleaning efficacy, reduces risks, and optimizes production efficiency in the pharmaceutical industry.

Understanding the key elements in the handover stage of a technology transfer is critical to your success. This is an overview of the Handover Stage of PDA TR-65.

Learn about the significance of residue removal, how it is effectively performed in cleanrooms to ensure the compliance of biosafety cabinets, and the impact of proper residue removal.

In response to a 2023 Open Letter from leading pharma companies, CDMOs are determining how to adapt their SOPs to improve sustainability and reduce CO2 emissions.

Explore the latest trends and strategic collaborations driving groundbreaking pharmaceutical advancements and their profound impact on the future of medicine and patient care.

Explore key obstacles—such as opalescence, viscosity, and aggregation—and real-world case studies on how composition changes during the concentration process can be effectively characterized.

Ensuring critical oral solid dosage (OSD) therapeutics reach patients successfully relies on the ability of developers and manufacturers to navigate the inherent issues surrounding their increasing complexity.

Discover how you can achieve a final mAb concentration above 200 g/L while maintaining critical quality attributes.

See a quick visual summary of findings from an early feasibility clinical study featuring a 2-5 mL wearable injector with a viscous placebo.

Gain insight into how a leading pharmaceutical company identified the root cause of long-standing inefficiencies and optimized performance and productivity with unprecedented speed and accuracy.

In this session, an expert walks you through the purity testing process and explains identification methods for biological indicators to help end users.

Explore an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability.

Ratnakar Potla of Genentech explains how Organ-Chips enable scientists to obtain a wider variety of multiomics data to better understand biological processes.

Through a breadth of facilities, resources, and experience, see how one CDMO ensure supply chain efficiency, safety, and security throughout the product development journey.